Pemetrexed, an anionic anticancer drug with a narrow therapeutic index, is eliminated mainly
by active renal tubular secretion. The in vitro to in vivo extrapolation approach used in this …

Purpose: This phase I study evaluated the effect of folate supplementation on the toxicity,
tolerability, and pharmacokinetics of pemetrexed in patients with locally advanced or metastatic …

A proof of concept study was conducted to investigate the safety and tolerability of a novel
oral glucokinase activator, LY2599506, during multiple dose administration to healthy …

Purpose: Pemetrexed is established as first-line treatment with cisplatin for malignant pleural
mesothelioma and advanced nonsquamous non–small-cell lung cancer (NSCLC) and as …

Purpose To investigate the toxicity profile, activity, pharmacokinetics, and pharmacodynamics
of pemetrexed in leukemia. Patients and Methods Patients with refractory or relapsed …

… the difference between the binding of Kb-Ig to activated binding was measured by flow … of
monomeric Binding of labeled Kb-Ig loaded with (SIY)-SIYRYYGL, SIYKb-Ig (closed Kb-Ig Fab …

… , Kb-Ig, loaded with either a cognate or non-cognate peptide for binding CD8 R T cells. We
quantified the sensitivity of these Kb-… T-cell suspension with the Kb-Ig microarrays under mild …

… B, Dominant motif analysis for Kb-SIY and Kb-TRP2 … E, Vβ usage of Kb-SIY and Kb-TRP
between naïve and tumor… versus tumor-bearing responses with Kb-SIY and Kb-TRP2. (n = 3 …

… In this study, we present a patient with an 850-kb deletion containing the genes MKX, ARMC4,
MPP7, and possibly WAC. Our patient carries the smallest reported deletion involving the …

… -1.8 kb, whereas the mRNA mediating the response to BK had an apparent size of 4.4-4.6
kb. … The library contained greater than 90% inserts, with an average insert size of 1.9 kb. The …